Journal of Pediatric Hematology/Oncology · 2018 · 13 citations · 7 references
MedicineHematologyImmunologyHematopathologyPediatric HematologyStem Cell TransplantationAllogeneic Stem Cell TransplantationDonor MatchingGraft-versus-host DiseaseHematopoietic Stem Cell TransplantationPediatric TransplantationTransplant RejectionCurative InterventionCurative TherapyDonor Availability AssessmentPost-transplant CyclophosphamideSibling Donor MatchingStem Cell Donor MatchingTransplantation For Hematologic MalignanciesTransplantation Outcome Assessment
Allogeneic hematopoietic stem cell transplant (HSCT) has been known to be a curative therapy for patients with hemophagocytic lymphohistiocytosis (HLH) but donor availability is an issue. Haploidentical HSCT with posttransplant cyclophosphamide (PTCy) has been investigated as a feasible option for various malignant and nonmalignant conditions with reduced incidence of acute graft versus host disease (GVHD) and graft rejection. However, its use has not been described in children with HLH and here we describe 2 boys who underwent successful haploidentical HSCT with PTCy. None had acute GVHD and 1 had limited chronic GVHD. Both are alive and disease-free at follow-up of 912 and 239 days, respectively. Haploidentical HSCT with PTCy is a feasible option for children with HLH lacking a matched sibling donor.
7
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
Leo Luznik, Javier Bolaños‐Meade, Marianna Zahurak et al. · Blood · 2010 · 404 citations · Full text
Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis
Nichola Cooper, Kanchan Rao, Kimberly Gilmour et al. · Blood · 2005 · 189 citations · Full text
Medicine, Hematology, Immunology +16